From Barefoot Doctors to Biologics: Dr. Ruby Wang on China's Healthcare Revolution

China’s healthcare system has undergone a radical transformation, evolving from a reliance on "barefoot doctors" and generic drug manufacturing to becoming a global leader in complex biologics and cancer therapies. This shift is driven by a confluence of demographic pressures, crisis-induced regulatory reforms, long-term state planning, and unique cultural approaches to patient care and data integration. Dr. Ruby Wang, a practicing physician and author of *China Cure*, highlights how Chinese biotech companies now command significant global licensing deals, challenging Western dominance in the pharmaceutical sector. While digital health platforms like Antafu have streamlined access through AI-driven clinical interactions, the system faces ongoing challenges, including clinician burnout, workplace violence, and the digital divide for an aging population. These developments reflect a broader, rapid modernization that continues to reshape both the domestic medical landscape and international pharmaceutical markets.